

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/705, C12N 15/00, C12Q 1/00		A1	(11) International Publication Number: WO 95/13299
			(43) International Publication Date: 18 May 1995 (18.05.95)
(21) International Application Number: PCT/US94/12859			(74) Agent: REITER, Stephen, E.; Pretty, Schroeder, Brueggemann & Clark, Suite 2000, 444 South Flower Street, Los Angeles, CA 90071 (US).
(22) International Filing Date: 8 November 1994 (08.11.94)			
(30) Priority Data: 08/149,503 8 November 1993 (08.11.93) US			
(60) Parent Application or Grant (63) Related by Continuation US 08/149,503 (CON) Filed on 8 November 1993 (08.11.93)			
(71) Applicant (for all designated States except US): THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC. [US/US]; 505 Coast Boulevard, South, La Jolla, CA 92037-4641 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): ELLIOTT, Kathryn, J. [US/US]; 3854 Baker Street, San Diego, CA 92117 (US). ELLIS, Steven, B. [US/US]; 8939 Oviedo Street, San Diego, CA 92129 (US). HARPOLD, Michael, M. [US/US]; 15630 Creek Hills Road, El Cajon, CA 92021 (US).			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).
Published With international search report.			
(54) Title: HUMAN NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR COMPOSITIONS AND METHODS EMPLOYING SAME			
(57) Abstract DNA encoding human neuronal nicotinic acetylcholine receptor α_2 subunits, mammalian and amphibian cells containing said DNA, and methods for producing such subunits are provided. In addition, combinations of subunits (i.e., α_2 , plus α_1 , α_3 , α_4 , and/or α_7 subunits in combination with β_2 , β_3 and/or β_4 subunits) are provided.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HUMAN NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR
COMPOSITIONS AND METHODS EMPLOYING SAME

RELATED APPLICATIONS

This application is related to United States
Serial Nos. 07/504,455, filed April 3, 1990, now pending;
07/938,154, filed November 30, 1992, now pending; and
5 08/028,031, filed March 8, 1993, now pending.

FIELD OF INVENTION

This invention relates to nucleic acids
encoding human neuronal nicotinic acetylcholine receptor
protein subunits, as well as the proteins themselves. In
10 particular, nucleic acids encoding human neuronal
nicotinic acetylcholine receptor alpha subunits and beta
subunits, and alpha subunit proteins, beta subunit
proteins, and combinations thereof are provided.

BACKGROUND OF THE INVENTION

15 Ligand-gated ion channels provide a means for
communication between cells of the central nervous
system. These channels convert a signal (e.g., a
chemical referred to as a neurotransmitter) that is
released by one cell into an electrical signal that
20 propagates along a target cell membrane. A variety of
neurotransmitters and neurotransmitter receptors exist in
the central and peripheral nervous systems. Five
families of ligand-gated receptors, including the
nicotinic acetylcholine receptors (NACHRs) of
25 neuromuscular and neuronal origins, have been identified
(Stroud et al. (1990) Biochemistry 29:11009-11023).
There is, however, little understanding of the manner in
which the variety of receptors generates different
responses to neurotransmitters or to other modulating
30 ligands in different regions of the nervous system.

The nicotinic acetylcholine receptors (NACHRs) are multisubunit proteins of neuromuscular and neuronal origins. These receptors form ligand-gated ion channels that mediate synaptic transmission between nerve and muscle and between neurons upon interaction with the neurotransmitter acetylcholine (ACh). Since various nicotinic acetylcholine receptor (NACHR) subunits exist, a variety of NACHR compositions (i.e., combinations of subunits) exist. The different NACHR compositions exhibit different specificities for various ligands and are thereby pharmacologically distinguishable. Thus, the nicotinic acetylcholine receptors expressed at the vertebrate neuromuscular junction in vertebrate sympathetic ganglia and in the vertebrate central nervous system have been distinguished on the basis of the effects of various ligands that bind to different NACHR compositions. For example, the elapid α -neurotoxins that block activation of nicotinic acetylcholine receptors at the neuromuscular junction do not block activation of some neuronal nicotinic acetylcholine receptors that are expressed on several different neuron-derived cell lines.

Muscle NACHR is a glycoprotein composed of five subunits with the stoichiometry $\alpha_2\beta(\gamma \text{ or } \epsilon)\delta$. Each of the subunits has a mass of about 50-60 kilodaltons (kd) and is encoded by a different gene. The $\alpha_2\beta(\gamma \text{ or } \epsilon)\delta$ complex forms functional receptors containing two ligand binding sites and a ligand-gated transmembrane channel. Upon interaction with a cholinergic agonist, muscle nicotinic AChRs conduct sodium ions. The influx of sodium ions rapidly short-circuits the normal ionic gradient maintained across the plasma membrane, thereby depolarizing the membrane. By reducing the potential difference across the membrane, a chemical signal is transduced into an electrical signal that signals muscle contraction at the neuromuscular junction.

Functional muscle nicotinic acetylcholine receptors have been formed with $\alpha\beta\delta\gamma$ subunits, $\alpha\beta\gamma$ subunits, $\alpha\beta\delta$ subunits, $\alpha\delta\gamma$ subunits or $\alpha\delta$ subunits, but not with only one subunit (see e.g., Kurosaki et al. (1987) FEBS Lett. 214: 253-258; Camacho et al. (1993) J. Neuroscience 13:605-613). In contrast, functional neuronal AChRs (nAChRs) can be formed from α subunits alone or combinations of α and β subunits. The larger α subunit is generally believed to be the ACh-binding subunit and the lower molecular weight β subunit is generally believed to be the structural subunit, although it has not been definitively demonstrated that the β subunit does not have the ability to bind ACh. Each of the subunits which participate in the formation of a functional ion channel are, to the extent they contribute to the structure of the resulting channel, "structural" subunits, regardless of their ability (or inability) to bind ACh. Neuronal AChRs (nAChRs), which are also ligand-gated ion channels, are expressed in ganglia of the autonomic nervous system and in the central nervous system (where they mediate signal transmission), in post-synaptic locations (where they modulate transmission), and in pre- and extra-synaptic locations (where they may have additional functions).

DNA encoding NACHRs has been isolated from several sources. Based on the information available from such work, it has been evident for some time that NACHRs expressed in muscle, in autonomic ganglia, and in the central nervous system are functionally diverse. This functional diversity could be due, at least in part, to the large number of different NACHR subunits which exist. There is an incomplete understanding, however, of how (and which) NACHR subunits combine to generate unique NACHR subtypes, particularly in neuronal cells. Indeed, there is evidence that only certain NACHR subtypes may be involved in diseases such as Alzheimer's disease.

Moreover, it is not clear whether NACHRs from analogous tissues or cell types are similar across species.

Accordingly, there is a need for the isolation and characterization of nucleic acids encoding each human neuronal NACHR subunit, recombinant cells containing such subunits and receptors prepared therefrom. In order to study the function of human neuronal AChRs and to obtain disease-specific pharmacologically active agents, there is also a need to obtain isolated (preferably purified) human neuronal nicotinic AChRs, and isolated (preferably purified) human neuronal nicotinic AChR subunits. In addition, there is also a need to develop assays to identify such pharmacologically active agents.

The availability of such nucleic acids, cells, receptor subunits and receptor compositions will eliminate the uncertainty of speculating as to human nNACHR structure and function based on predictions drawn from non-human nNACHR data, or human or non-human muscle or ganglia NACHR data.

Therefore, it is an object herein to isolate and characterize nucleic acids encoding subunits of human neuronal nicotinic acetylcholine receptors. It is also an object herein to provide methods for recombinant production of human neuronal nicotinic acetylcholine receptor subunits. It is also an object herein to provide purified receptor subunits and to provide methods for screening compounds to identify compounds that modulate the activity of human neuronal AChRs.

These and other objects will become apparent to those of skill in the art upon further study of the specification and claims.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided isolated nucleic acids encoding novel human alpha subunits of neuronal NACHRs. In particular,
5 isolated DNA encoding human α_2 subunits of neuronal NACHRs are provided. Messenger RNA and polypeptides encoded by the above-described nucleic acids are also provided.

Further in accordance with the present invention, there are provided recombinant α_2 subunits of
10 human neuronal nicotinic AChRs, as well as methods for the production thereof. In addition, recombinant neuronal nicotinic acetylcholine receptors containing a human α_2 subunit of neuronal nicotinic AChRs are also provided, as well as methods for the production thereof.
15 Further provided are recombinant neuronal nicotinic AChRs that contain a mixture of one or more NACHR subunits encoded by a host cell, and one or more nNACHR subunits encoded by heterologous DNA or RNA (i.e., DNA or RNA as described herein that has been introduced into the host
20 cell), as well as methods for the production thereof.

Plasmids containing DNA encoding the above-described subunits are also provided. Recombinant cells containing the above-described DNA, mRNA or plasmids are also provided herein. Such cells are useful, for
25 example, for replicating DNA, for producing human NACHR subunits and recombinant receptors, and for producing cells that express receptors containing one or more human subunits.

Also provided in accordance with the present
30 invention are methods for identifying cells that express functional nicotinic acetylcholine receptors. Methods for identifying compounds which modulate the activity of NACHRs are also provided.

The DNA, mRNA, vectors, receptor subunits, receptor subunit combinations and cells provided herein permit production of selected neuronal nicotinic AChR subunits and specific combinations thereof, as well as
5 antibodies to said receptor subunits. This provides a means to prepare synthetic or recombinant receptors and receptor subunits that are substantially free of contamination from many other receptor proteins whose presence can interfere with analysis of a single NACHR
10 subtype. The availability of desired receptor subtypes makes it possible to observe the effect of a drug substance on a particular receptor subtype and to thereby perform initial *in vitro* screening of the drug substance in a test system that is specific for humans and specific
15 for a human neuronal nicotinic AChR subtype.

The availability of subunit-specific antibodies makes possible the application of the technique of immunohistochemistry to monitor the distribution and expression density of various subunits (e.g., in normal
20 vs diseased brain tissue). Such antibodies could also be employed for diagnostic and therapeutic applications.

The ability to screen drug substances *in vitro* to determine the effect of the drug on specific receptor compositions should permit the development and screening
25 of receptor subtype-specific or disease-specific drugs. Also, testing of single receptor subunits or specific receptor subunit combinations with a variety of potential agonists or antagonists provides additional information with respect to the function and activity of the
30 individual subunits and should lead to the identification and design of compounds that are capable of very specific interaction with one or more of the receptor subunits or receptor subtypes. The resulting drugs should exhibit fewer unwanted side effects than drugs identified by
35 screening with cells that express a variety of subtypes.

Further in relation to drug development and therapeutic treatment of various disease states, the availability of nucleic acids encoding human nNACHR subunits enables identification of any alterations in such genes (e.g., mutations) which may correlate with the occurrence of certain disease states. In addition, the creation of animal models of such disease states becomes possible, by specifically introducing such mutations into synthetic DNA sequences which can then be introduced into laboratory animals or *in vitro* assay systems to determine the effects thereof.

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 presents a restriction map of two pCMV promoter-based vectors, pCMV-T7-2 and pCMV-T7-3.

15

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have isolated and characterized nucleic acids encoding a novel human alpha subunit of neuronal NACHRs. Specifically, isolated DNAs encoding a human α_2 subunit of neuronal NACHRs are described herein. Recombinant messenger RNA (mRNA) and recombinant polypeptides encoded by the above-described nucleic acids are also provided.

As used herein, isolated (or substantially pure) as a modifier of DNA, RNA, polypeptides or proteins means that the DNA, RNA, polypeptides or proteins so designated have been separated from their *in vivo* cellular environments through the efforts of human beings. Thus as used herein, isolated (or substantially pure) DNA refers to DNAs purified according to standard techniques employed by those skilled in the art (see, e.g., Maniatis et al.(1982) Molecular Cloning: A

Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

Similarly, as used herein, "recombinant" as a modifier of DNA, RNA, polypeptides or proteins means that the DNA, RNA, polypeptides or proteins so designated have been prepared by the efforts of human beings, e.g., by cloning, recombinant expression, and the like. Thus as used herein, recombinant proteins, for example, refers to proteins produced by a recombinant host, expressing DNAs which have been added to that host through the efforts of human beings.

As used herein, a human alpha subunit gene is a gene that encodes an alpha subunit of a human neuronal nicotinic acetylcholine receptor. The alpha subunit is a subunit of the nAChR to which ACh binds. Assignment of the name "alpha" to a putative nAChR subunit, according to Deneris et al. [Tips (1991) 12:34-40], is based on the conservation of adjacent cysteine residues in the presumed extracellular domain of the subunit that are the homologues of cysteines 192 and 193 of the *Torpedo* alpha subunit (see Noda et al. (1982) *Nature* 299:793-797). As used herein, an alpha subunit refers to a human nAChR subunit that is encoded by DNA that hybridizes under high stringency conditions to the nAChR alpha subunit-encoding DNAs disclosed herein. An alpha subunit also binds to ACh under physiological conditions and at physiological concentrations and, in the optional presence of a beta subunit (i.e., some alpha subunits are functional alone, while others require the presence of a beta subunit), generally forms a functional AChR as assessed by methods described herein or known to those of skill in this art.

As used herein, " α_2 subunit DNA" refers to DNA encoding a neuronal nicotinic acetylcholine receptor

subunit of the same name. Such DNA can be characterized in a number of ways, for example, the nucleotides of said DNA may encode the amino acid sequence set forth in SEQ. ID No. 2. Presently preferred α_2 -encoding DNAs can be

5 characterized as DNA which hybridizes under high stringency conditions to the coding sequence set forth in SEQ. ID No. 1 (preferably to substantially the entire coding sequence thereof, i.e., nucleotides 166-1755). Especially preferred α_2 -encoding DNAs of the invention are

10 characterized as having substantially the same nucleotide sequence as the coding region set forth in SEQ. ID No. 1 (i.e., nucleotides 166-1755 thereof).

Typically, unless an α_2 subunit arises as a splice variant, α_2 -encoding DNA will share substantial

15 sequence homology (i.e., greater than about 90%), with the α_4 DNAs described herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA provided herein, but such a splice variant would include regions of nearly 100%

20 homology to the above-described DNAs.

Also contemplated are alpha subunits encoded by DNAs that encode alpha subunits as defined above, but that by virtue of degeneracy of the genetic code do not necessarily hybridize to the disclosed DNA or deposited

25 clones under specified hybridization conditions. Such subunits also contribute to the formation of a functional receptor, as assessed by the methods described herein or known to those of skill in the art, generally with one or more beta subunits. Typically, unless an alpha subunit

30 is encoded by RNA that arises from alternative splicing (i.e., a splice variant), alpha-encoding DNA and the alpha subunit encoded thereby share substantial sequence homology with the alpha subunit DNAs (and proteins encoded thereby) described herein. It is understood that

35 DNA or RNA encoding a splice variant may overall share

less than 90% homology with the DNA or RNA provided herein, but include regions of nearly 100% homology to a DNA fragment described herein, and encode an open reading frame that includes start and stop codons and encodes a
5 functional alpha subunit.

As used herein, a splice variant refers to variant NACHR subunit-encoding nucleic acid(s) produced by differential processing of primary transcript(s) of genomic DNA, resulting in the production of more than one
10 type of mRNA. cDNA derived from differentially processed genomic DNA will encode NACHR subunits that have regions of complete amino acid identity and regions having different amino acid sequences. Thus, the same genomic sequence can lead to the production of multiple, related
15 mRNAs and proteins. Both the resulting mRNAs and proteins are referred to herein as "splice variants".

Stringency of hybridization is used herein to refer to conditions under which polynucleic acid hybrids are stable. As known to those of skill in the art, the
20 stability of hybrids is reflected in the melting temperature (T_m) of the hybrids. T_m can be approximated by the formula:

$$81.5^{\circ}\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G+C) - 600/l,$$

where l is the length of the hybrids in nucleotides. T_m
25 decreases approximately 1-1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of lower stringency, followed
30 by washes of varying, but higher, stringency. Reference to hybridization stringency relates to such washing conditions. Thus, as used herein:

- 5 (1) HIGH STRINGENCY refers to conditions that permit hybridization of only those nucleic acid sequences that form stable hybrids in 0.018M NaCl at 65°C (i.e., if a hybrid is not stable in 0.018M NaCl at 65°C, it will not be stable under high stringency conditions, as contemplated herein). High stringency conditions can be provided, for example, by hybridization in 50%
10 formamide, 5X Denhardt's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.1X SSPE, and 0.1% SDS at 65°C;
- 15 (2) MODERATE STRINGENCY refers to conditions equivalent to hybridization in 50% formamide, 5X Denhardt's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.2X SSPE, 0.2% SDS, at 65°C; and
- 20 (3) LOW STRINGENCY refers to conditions equivalent to hybridization in 10% formamide, 5X Denhardt's solution, 6X SSPE, 0.2% SDS, followed by washing in 1X SSPE, 0.2% SDS, at 50°C.

25 It is understood that these conditions may be duplicated using a variety of buffers and temperatures and that they are not necessarily precise.

Denhardt's solution and SSPE (see, e.g., Sambrook, Fritsch, and Maniatis, in: Molecular Cloning,
30 A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989) are well known to those of skill in the art as are other suitable hybridization buffers. For example, SSPE is pH 7.4 phosphate-buffered 0.18M NaCl. SSPE can be

prepared, for example, as a 20X stock solution by dissolving 175.3 g of NaCl, 27.6 g of NaH_2PO_4 and 7.4 g EDTA in 800 ml of water, adjusting the pH to 7.4, and then adding water to 1 liter. Denhardt's solution (see, 5 Denhardt (1966) Biochem. Biophys. Res. Commun. 23:641) can be prepared, for example, as a 50X stock solution by mixing 5 g Ficoll (Type 400, Pharmacia LKB Biotechnology, INC., Piscataway NJ), 5 g of polyvinylpyrrolidone, 5 g bovine serum albumin (Fraction V; Sigma, St. Louis MO) 10 water to 500 ml and filtering to remove particulate matter.

The phrase "substantial sequence homology" is used herein in reference to the nucleotide sequence of DNA, the ribonucleotide sequence of RNA, or the amino 15 acid sequence of protein, that have slight and non-consequential sequence variations from the actual sequences disclosed herein. Species having substantial sequence homology are considered to be equivalent to the disclosed sequences and as such are within the scope of 20 the appended claims. In this regard, "slight and non-consequential sequence variations" mean that "homologous" sequences, i.e., sequences that have substantial homology with the DNA, RNA, or proteins disclosed and claimed herein, are functionally equivalent to the sequences 25 disclosed and claimed herein. Functionally equivalent sequences will function in substantially the same manner to produce substantially the same compositions as the nucleic acid and amino acid compositions disclosed and claimed herein. In particular, functionally equivalent 30 DNAs encode proteins that are the same as those disclosed herein or that have conservative amino acid variations, such as substitution of a non-polar residue for another non-polar residue or a charged residue for a similarly charged residue. These changes include those recognized 35 by those of skill in the art as those that do not

substantially alter the tertiary structure of the protein.

In practice, the term substantially the same sequence means that DNA or RNA encoding two proteins
5 hybridize under conditions of high stringency and encode proteins that have the same sequence of amino acids or have changes in sequence that do not alter their structure or function. As used herein, substantially identical sequences of nucleotides share at least about
10 90% identity, and substantially identical amino acid sequences share more than 95% amino acid identity. It is recognized, however, that proteins (and DNA or mRNA encoding such proteins) containing less than the above-described level of homology arising as splice variants or
15 that are modified by conservative amino acid substitutions (or substitution of degenerate codons) are contemplated to be within the scope of the present invention.

DNA encoding human neuronal nicotinic AChR α_2
20 subunits may be isolated by screening suitable human cDNA or human genomic libraries under suitable hybridization conditions with DNA disclosed herein. Suitable libraries can be prepared from neuronal tissue samples, hippocampus tissue, or cell lines, such as the human neuroblastoma
25 cell line IMR32 (ATCC Accession No. CCL127), and the like. The library is preferably screened with a portion of DNA including the entire subunit-encoding sequence thereof, or the library may be screened with a suitable probe.

30 As used herein, a probe is single-stranded DNA or RNA that has a sequence of nucleotides that includes at least 14 contiguous bases that are the same as (or the complement of) any 14 bases set forth in SEQ ID No. 1. Preferred regions from which to construct probes include

5' and/or 3' coding sequences, sequences predicted to encode transmembrane domains, sequences predicted to encode the cytoplasmic loop, signal sequences, acetylcholine (ACh) and α -bungarotoxin (α -bgtx) binding sites, and the like. Amino acids 210-220 are typically involved in ACh and α -bgtx binding. The approximate amino acid residues which comprise such regions specifically for α_2 subunits include amino acids 1-55 for the signal sequence, amino acids 264-289 for the first transmembrane domain (TMD1), amino acids 297-320 for the second transmembrane domain (TMD2), amino acids 326-350 for the third transmembrane domain (TMD3), amino acids 444-515 for the fourth transmembrane domain (TMD4), and amino acids 351-443 for the cytoplasmic loop. Alternatively, portions of the DNA can be used as primers to amplify selected fragments in a particular library.

After screening the library, positive clones are identified by detecting a hybridization signal; the identified clones are characterized by restriction enzyme mapping and/or DNA sequence analysis, and then examined, by comparison with the sequences set forth herein, to ascertain whether they include DNA encoding a complete alpha subunit. If the selected clones are incomplete, they may be used to rescreen the same or a different library to obtain overlapping clones. If desired, the library can be rescreened with positive clones until overlapping clones that encode an entire alpha subunit are obtained. If the library is a cDNA library, then the overlapping clones will include an open reading frame. If the library is genomic, then the overlapping clones may include exons and introns. In both instances, complete clones may be identified by comparison with the DNA and encoded proteins provided herein.

Complementary DNA clones encoding human nNACHR α_2 subunits have been isolated. The DNA clones provided

herein may be used to isolate genomic clones encoding such subunits and to isolate any splice variants by screening libraries prepared from different neural tissues. Nucleic acid amplification techniques, which
5 are well known in the art, can be used to locate splice variants of human NACHR subunits. This is accomplished by employing oligonucleotides based on DNA sequences surrounding divergent sequence(s) as primers for amplifying human RNA or genomic DNA. Size and sequence
10 determinations of the amplification products can reveal the existence of splice variants. Furthermore, isolation of human genomic DNA sequences by hybridization can yield DNA containing multiple exons, separated by introns, that correspond to different splice variants of transcripts
15 encoding human NACHR subunits.

The above-described nucleotide sequences can be incorporated into vectors for further manipulation. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous DNA into
20 cells for either expression or replication thereof. Selection and use of such vehicles are well within the level of skill of the art.

An expression vector includes vectors capable of expressing DNAs that are operatively linked with
25 regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an
30 appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which
35 integrate into the host cell genome. Presently preferred

plasmids for expression of invention AChR subunits in eukaryotic host cells, particularly mammalian cells, include cytomegalovirus (CMV) promoter-containing vectors such as pCMV, pcDNA1, and the like.

5 As used herein, a promoter region refers to a segment of DNA that controls transcription of DNA to which it is operatively linked. The promoter region includes specific sequences that are sufficient for RNA polymerase recognition, binding and transcription
10 initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of RNA polymerase. These sequences may be *cis* acting or may be
15 responsive to *trans* acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated. Exemplary promoters contemplated for use in the practice of the present invention include the SV40 early promoter, the cytomegalovirus (CMV) promoter, the
20 mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, and the like.

 As used herein, the term "operatively linked" refers to the functional relationship of DNA with
25 regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences. For example, operative linkage of DNA to a promoter refers to the physical and functional relationship between the DNA and
30 the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA. In order to optimize expression and/or *in vitro* transcription, it may be necessary to remove or alter 5'
35 untranslated portions of the clones to remove extra,

potential alternative translation initiation (i.e., start) codons or other sequences that interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites (see, for example, Kozak (1991) J. Biol. Chem. 266:19867-19870) can be inserted immediately 5' of the start codon to enhance expression. The desirability of (or need for) such modification may be empirically determined.

10 As used herein, expression refers to the process by which polynucleic acids are transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the polynucleic acid is derived from genomic DNA, expression may, if an appropriate eukaryotic host cell or organism is selected, include splicing of the mRNA.

Particularly preferred vectors for transfection of mammalian cells are the pSV2dhfr expression vectors, which contain the SV40 early promoter, mouse dhfr gene, 20 SV40 polyadenylation and splice sites and sequences necessary for maintaining the vector in bacteria, cytomegalovirus (CMV) promoter-based vectors such as pCDNA1 (Invitrogen, San Diego, CA), and MMTV promoter-based vectors such as pMSG (Catalog No. 27-4506-01 from 25 Pharmacia, Piscataway, NJ).

Full-length DNAs encoding human neuronal NACHR subunits have been inserted into vector pCMV-T7, a pUC19-based mammalian cell expression vector containing the CMV promoter/enhancer, SV40 splice/donor sites located 30 immediately downstream of the promoter, a polylinker downstream of the splice/donor sites, followed by an SV40 polyadenylation signal. Placement of NACHR subunit DNA between the CMV promoter and SV40 polyadenylation signal provides for constitutive expression of the foreign DNA

in a mammalian host cell transfected with the construct. For inducible expression of human NACHR subunit-encoding DNA in a mammalian cell, the DNA can be inserted into a plasmid such as pMSG. This plasmid contains the mouse
5 mammary tumor virus (MMTV) promoter for steroid-inducible expression of operatively associated foreign DNA. If the host cell does not express endogenous glucocorticoid receptors required for uptake of glucocorticoids (i.e., inducers of the MMTV promoter) into the cell, it is
10 necessary to additionally transfect the cell with DNA encoding the glucocorticoid receptor (ATCC accession no. 67200). Full-length human DNA clones encoding human α_2 subunits can also be subcloned into pIBI24 (International Biotechnologies, Inc., New Haven, CT) or pCMV-T7-2 for
15 synthesis of *in vitro* transcripts.

In accordance with another embodiment of the present invention, there are provided cells containing the above-described polynucleic acids (i.e., DNA or mRNA). Such host cells as bacterial, yeast and mammalian
20 cells can be used for replicating DNA and producing nACHR subunit(s). Methods for constructing expression vectors, preparing *in vitro* transcripts, transfecting DNA into mammalian cells, injecting oocytes, and performing electrophysiological and other analyses for assessing
25 receptor expression and function as described herein are also described in PCT Application Nos. PCT/US91/02311, PCT/US91/05625 and PCT/US92/11090, and in co-pending U.S. Application Serial Nos. 07/504,455, 07/563,751 and 07/812,254. The subject matter of these applications are
30 hereby incorporated by reference herein in their entirety.

Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasmid vectors,
35 each encoding one or more distinct genes or with linear

DNA, and selection of transfected cells are well known in the art (see, e.g., Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press). Heterologous DNA may be

5 introduced into host cells by any method known to those of skill in the art, such as transfection with a vector encoding the heterologous DNA by CaPO_4 precipitation (see, e.g., Wigler et al. (1979) Proc. Natl. Acad. Sci. 76:1373-1376). Recombinant cells can then be cultured

10 under conditions whereby the subunit(s) encoded by the DNA is (are) expressed. Preferred cells include mammalian cells (e.g., HEK 293, CHO and Ltk⁻ cells), yeast cells (e.g., methylotrophic yeast cells, such as *Pichia pastoris*), bacterial cells (e.g., *Escherichia coli*), and

15 the like.

While the DNA provided herein may be expressed in any eukaryotic cell, including yeast cells (such as, for example, *P. pastoris* (see U.S. Patent Nos. 4,882,279, 4,837,148, 4,929,555 and 4,855,231), *Saccharomyces*

20 *cerevisiae*, *Candida tropicalis*, *Hansenula polymorpha*, and the like), mammalian expression systems, including commercially available systems and other such systems known to those of skill in the art, for expression of DNA encoding the human neuronal nicotinic AChR subunits

25 provided herein are presently preferred. *Xenopus* oocytes are preferred for expression of RNA transcripts of the DNA.

In preferred embodiments, DNA is ligated into a vector, and introduced into suitable host cells to

30 produce transformed cell lines that express a specific human nNACHR receptor subtype, or specific combinations of subtypes. The resulting cell lines can then be produced in quantity for reproducible quantitative analysis of the effects of drugs on receptor function.

35 In other embodiments, mRNA may be produced by *in vitro*

transcription of DNA encoding each subunit. This mRNA, either from a single subunit clone or from a combination of clones, can then be injected into *Xenopus* oocytes where the mRNA directs the synthesis of the human
5 receptor subunits, which then form functional receptors. Alternatively, the subunit-encoding DNA can be directly injected into oocytes for expression of functional receptors. The transfected mammalian cells or injected oocytes may then be used in the methods of drug screening
10 provided herein.

Cloned full-length DNA encoding any human neuronal nicotinic AChR subunit(s) may be introduced into a plasmid vector for expression in a eukaryotic cell. Such DNA may be genomic DNA or cDNA. Host cells may be
15 transfected with one or a combination of plasmids, each of which encodes at least one human neuronal nicotinic AChR subunit.

Eukaryotic cells in which DNA or RNA may be introduced include any cells that are transfectable by
20 such DNA or RNA or into which such DNA or RNA may be injected. Preferred cells are those that can be transiently or stably transfected and also express the DNA and RNA. Presently most preferred cells are those that can form recombinant or heterologous human neuronal
25 nicotinic AChRs comprising one or more subunits encoded by the heterologous DNA. Such cells may be identified empirically or selected from among those known to be readily transfected or injected.

Exemplary cells for introducing DNA include
30 cells of mammalian origin (e.g., COS cells, mouse L cells, Chinese hamster ovary (CHO) cells, human embryonic kidney cells, African green monkey cells and other such cells known to those of skill in the art), amphibian cells (e.g., *Xenopus laevis* oocytes), yeast cells (e.g.,

Saccharomyces cerevisiae, *Pichia pastoris*), and the like. Exemplary cells for expressing injected RNA transcripts include *Xenopus laevis* oöcytes. Cells that are preferred for transfection of DNA are known to those of skill in the art or may be empirically identified, and include HEK 293 (which are available from ATCC under accession #CRL 1573); Ltk⁻ cells (which are available from ATCC under accession #CCL1.3); COS-7 cells (which are available from ATCC under accession #CRL 1651); and DG44 cells (dhfr⁻ CHO cells; see, e.g., Urlaub et al. (1986) Cell. Molec. Genet. 12: 555). Presently preferred cells include DG44 cells and HEK 293 cells, particularly HEK 293 cells that have been adapted for growth in suspension and that can be frozen in liquid nitrogen and then thawed and regrown. HEK 293 cells are described, for example, in U.S. Patent No. 5,024,939 to Gorman (see, also, Stillman et al. (1985) Mol. Cell. Biol. 5:2051-2060).

DNA may be stably incorporated into cells or may be transiently introduced using methods known in the art. Stably transfected mammalian cells may be prepared by transfecting cells with an expression vector having a selectable marker gene (such as, for example, the gene for thymidine kinase, dihydrofolate reductase, neomycin resistance, and the like), and growing the transfected cells under conditions selective for cells expressing the marker gene. To produce such cells, the cells should be transfected with a sufficient concentration of subunit-encoding nucleic acids to form human neuronal nicotinic AChRs that contain the human subunits encoded by heterologous DNA. The precise amounts and ratios of DNA encoding the subunits may be empirically determined and optimized for a particular combination of subunits, cells and assay conditions. Recombinant cells that express neuronal nicotinic AChR containing subunits encoded only by the heterologous DNA or RNA are especially preferred.

Heterologous DNA may be maintained in the cell as an episomal element or may be integrated into chromosomal DNA of the cell. The resulting recombinant cells may then be cultured or subcultured (or passaged, 5 in the case of mammalian cells) from such a culture or a subculture thereof. Methods for transfection, injection and culturing recombinant cells are known to the skilled artisan. Similarly, the human neuronal nicotinic AChR subunits may be purified using protein purification 10 methods known to those of skill in the art. For example, antibodies or other ligands that specifically bind to one or more of the subunits may be used for affinity purification of the subunit or human neuronal nicotinic AChRs containing the subunits.

15 In accordance with one embodiment of the present invention, methods for producing cells that express human neuronal nicotinic AChR subunits and functional receptors are also provided. In one such method, host cells are transfected with DNA encoding an α_2 20 subunit of a neuronal nicotinic acetylcholine receptor and a beta subunit of a neuronal nicotinic acetylcholine receptor. Using methods such as northern blot or slot blot analysis, transfected cells that contain alpha α_2 and, optionally, beta subunit encoding DNA or RNA, can be 25 selected. Transfected cells are also analyzed to identify those that express NACHR protein. Analysis can be carried out, for example, by measuring the ability of cells to bind acetylcholine, nicotine, or a nicotine agonist, compared to the nicotine binding ability of 30 untransfected host cells or other suitable control cells, by electrophysiologically monitoring the currents through the cell membrane in response to a nicotine agonist, and the like.

As used herein, a human beta subunit gene is a 35 gene that encodes a beta subunit of a human neuronal

nicotinic acetylcholine receptor. Assignment of the name "beta" to a putative nNACHR subunit, according to Deneris et al. supra, is based on the lack of adjacent cysteine residues (which are characteristic of alpha subunits).

- 5 The beta subunit is frequently referred to as the structural NACHR subunit (although it is possible that beta subunits also have ACh binding properties). Combination of beta subunit(s) with appropriate alpha subunit(s) leads to the formation of a functional
- 10 receptor. A beta subunit forms a functional NACHR, as assessed by methods described herein or known to those of skill in this art, with appropriate alpha subunit subtype(s).

- In particularly preferred aspects, eukaryotic
- 15 cells which contain heterologous DNAs express such DNA and form recombinant functional neuronal nicotinic AChR(s). In more preferred aspects, recombinant neuronal nicotinic AChR activity is readily detectable because it is a type that is absent from the untransfected host cell
- 20 or is of a magnitude not exhibited in the untransfected cell. Such cells that contain recombinant receptors could be prepared, for example, by causing cells transformed with DNA encoding human neuronal nicotinic AChR α_2 and β_2 subunits to express the corresponding
- 25 proteins. The resulting synthetic or recombinant receptor would contain only the α_2 and β_2 nNACHR subunits. Such a receptor would be useful for a variety of applications, e.g., as part of an assay system free of the interferences frequently present in prior art assay
- 30 systems employing non-human receptors or human tissue preparations. Furthermore, testing of single receptor subunits with a variety of potential agonists or antagonists would provide additional information with respect to the function and activity of the individual
- 35 subunits. Such information is expected to lead to the identification of compounds which are capable of very

specific interaction with one or more of the receptor subunits. Such specificity may prove of great value in medical application.

Thus, DNA encoding one or more human neuronal
5 nicotinic AChR subunits may be introduced into suitable host cells (e.g., eukaryotic or prokaryotic cells) for expression of individual subunits and functional NACHRs. Preferably combinations of alpha and beta subunits may be introduced into cells: such combinations include
10 combinations of α_2 , optionally in the further presence of any one or more of α_1 , α_3 , α_4 , α_5 and α_7 , with β_2 or β_4 .

Sequence information for α_1 is presented in Biochem. Soc. Trans. (1989) 17:219-220; sequence information for α_2 is presented herein; sequence
15 information for α_3 is presented in United States Serial No. 07/504,455, filed April 3, 1990, now pending; sequence information for α_4 is presented in United States Serial No. 08/028,031, filed March 8, 1993, now pending; sequence information for α_5 is presented in Proc. Natl.
20 Acad. Sci. USA (1992) 89:1572-1576; and sequence information for α_7 is presented in United States Serial No. 08/028,031, filed March 8, 1993, now pending.

Sequence information for β_2 is presented in United States Serial No. 07/504,455, filed April 3, 1990,
25 now pending; and sequence information for β_4 is presented in United States Serial No. 08/028,031, filed March 8, 1993, now pending.

In certain embodiments, eukaryotic cells with heterologous human neuronal nicotinic AChRs are produced
30 by introducing into the cell a first composition, which contains at least one RNA transcript that is translated in the cell into a subunit of a human neuronal nicotinic AChR. In preferred embodiments, the composition that is

introduced contains an RNA transcript which encodes a human α_2 subunit and also contains an RNA transcript which encodes a beta subunit of a human neuronal nicotinic AChR. RNA transcripts can be obtained from cells
5 transfected with DNAs encoding human neuronal nicotinic acetylcholine receptor subunits or by *in vitro* transcription of subunit-encoding DNAs. Methods for *in vitro* transcription of cloned DNA and injection of the resulting mRNA into eukaryotic cells are well known in
10 the art. Amphibian oocytes are particularly preferred for expression of *in vitro* transcripts of the human nNACHR DNA clones provided herein. See, for example, Dascal (1989) CRC Crit. Rev. Biochem. 22:317-387, for a review of the use of *Xenopus* oocytes to study ion
15 channels.

Thus, pairwise (or stepwise) introduction of DNA or RNA encoding alpha and beta subtypes into cells is possible. The resulting cells may be tested by the methods provided herein or known to those of skill in the
20 art to detect functional AChR activity. Such testing will allow the identification of pairs of alpha and beta subunit subtypes that produce functional AChRs, as well as individual subunits that produce functional AChRs.

~~As used herein, activity of a human neuronal~~
25 nicotinic AChR refers to any activity characteristic of an NACHR. Such activity can typically be measured by one or more *in vitro* methods, and frequently corresponds to an *in vivo* activity of a human neuronal nicotinic AChR. Such activity may be measured by any method known to
30 those of skill in the art, such as, for example, measuring the amount of current which flows through the recombinant channel in response to a stimulus.

Methods to determine the presence and/or activity of human neuronal nicotinic AChRs include assays

that measure nicotine binding, ^{86}Rb ion-flux, Ca^{2+} influx, the electrophysiological response of cells, the electrophysiological response of oocytes transfected with RNA from the cells, and the like. In particular, methods
5 are provided herein for the measurement or detection of an AChR-mediated response upon contact of cells containing the DNA or mRNA with a test compound.

As used herein, a recombinant or heterologous human neuronal nicotinic AChR refers to a receptor that
10 contains one or more subunits encoded by heterologous DNA that has been introduced into and expressed in cells capable of expressing receptor protein. A recombinant human neuronal nicotinic AChR may also include subunits that are produced by DNA endogenous to the host cell. In
15 certain embodiments, recombinant or heterologous human neuronal nicotinic AChR may contain only subunits that are encoded by heterologous DNA.

As used herein, heterologous or foreign DNA and RNA are used interchangeably and refer to DNA or RNA that
20 does not occur naturally as part of the genome of the cell in which it is present or to DNA or RNA which is found in a location or locations in the genome that differ from that in which it occurs in nature.

Typically, heterologous or foreign DNA and RNA refers to
25 DNA or RNA that is not endogenous to the host cell and has been artificially introduced into the cell. Examples of heterologous DNA include DNA that encodes a human neuronal nicotinic AChR subunit, DNA that encodes RNA or proteins that mediate or alter expression of endogenous
30 DNA by affecting transcription, translation, or other regulatable biochemical processes, and the like. The cell that expresses heterologous DNA may contain DNA encoding the same or different expression products. Heterologous DNA need not be expressed and may be

integrated into the host cell genome or maintained episomally.

Recombinant receptors on recombinant eukaryotic
5 cell surfaces may contain one or more subunits encoded by
the DNA or mRNA encoding human neuronal nicotinic AChR
subunits, or may contain a mixture of subunits encoded by
the host cell and subunits encoded by heterologous DNA or
mRNA. Recombinant receptors may be homogeneous or may
10 be a mixture of subtypes. Mixtures of DNA or mRNA
encoding receptors from various species, such as rats and
humans, may also be introduced into the cells. Thus, a
cell can be prepared that expresses recombinant receptors
containing only α_2 and either β_2 or β_4 subunits.

15 As used herein, a functional neuronal nicotinic
AChR is a receptor that exhibits an activity of neuronal
nicotinic AChRs as assessed by any *in vitro* or *in vivo*
assay disclosed herein or known to those of skill in the
art. Possession of any such activity that may be
20 assessed by any method known to those of skill in the art
and provided herein is sufficient to designate a receptor
as functional. Methods for detecting NACHR protein
and/or activity include, for example, assays that measure
nicotine binding, ^{86}Rb ion-flux, Ca^{2+} influx, the
25 electrophysiological response of cells containing
heterologous DNA or mRNA encoding one or more receptor
subunit subtypes, and the like. As used herein,
"functional" with respect to a recombinant or
heterologous human neuronal nicotinic AChR means that the
30 receptor channel is able to provide for and regulate
entry of human neuronal nicotinic AChR-permeable ions,
such as, for example, Na^+ , K^+ , Ca^{2+} or Ba^{2+} , in response to
a stimulus and/or bind ligands with affinity for the
receptor. Preferably such human neuronal nicotinic AChR
35 activity is distinguishable, such as by
electrophysiological, pharmacological and other means

known to those of skill in the art, from any endogenous nicotinic AChR activity that may be produced by the host cell.

In accordance with a particular embodiment of the present invention, recombinant human neuronal nicotinic AChR-expressing mammalian cells or oocytes can be contacted with a test compound, and the modulating effect(s) thereof can then be evaluated by comparing the AChR-mediated response in the presence and absence of test compound, or by comparing the AChR-mediated response of test cells, or control cells (i.e., cells that do not express nNACHRs), to the presence of the compound.

As used herein, a compound or signal that "modulates the activity of a neuronal nicotinic AChR" refers to a compound or signal that alters the activity of NACHR so that activity of the NACHR is different in the presence of the compound or signal than in the absence of the compound or signal. In particular, such compounds or signals include agonists and antagonists. The term agonist refers to a substance or signal, such as ACh, that activates receptor function; and the term antagonist refers to a substance that interferes with receptor function. Typically, the effect of an antagonist is observed as a blocking of activation by an agonist. Antagonists include competitive and non-competitive antagonists. A competitive antagonist (or competitive blocker) interacts with or near the site specific for the agonist (e.g., ligand or neurotransmitter) for the same or closely situated site. A non-competitive antagonist or blocker inactivates the functioning of the receptor by interacting with a site other than the site that interacts with the agonist.

As understood by those of skill in the art, assay methods for identifying compounds that modulate

human neuronal nicotinic AChR activity (e.g., agonists and antagonists) generally require comparison to a control. One type of a "control" cell or "control" culture is a cell or culture that is treated

5 substantially the same as the cell or culture exposed to the test compound, except the control culture is not exposed to test compound. For example, in methods that use voltage clamp electrophysiological procedures, the same cell can be tested in the presence and absence of

10 test compound, by merely changing the external solution bathing the cell. Another type of "control" cell or "control" culture may be a cell or a culture of cells which are identical to the transfected cells, except the cells employed for the control culture do not express

15 functional human neuronal nicotinic AChRs. In this situation, the response of test cell to test compound is compared to the response (or lack of response) of receptor-negative (control) cell to test compound, when cells or cultures of each type of cell are exposed to

20 substantially the same reaction conditions in the presence of compound being assayed.

Functional recombinant human neuronal nicotinic AChRs contemplated by the present invention include at least an α_2 subunit, or an α_2 subunit and a beta subunit

25 of a human neuronal nicotinic AChR. Eukaryotic cells expressing these subunits have been prepared by injection of RNA transcripts and by transfection of DNA. Such cells have exhibited nicotinic AChR activity attributable to human neuronal nicotinic AChRs that contain one or

30 more of the heterologous human neuronal nicotinic AChR subunits.

With respect to measurement of the activity of functional heterologous human neuronal nicotinic AChRs, endogenous AChR activity and, if desired, activity of

35 AChRs that contain a mixture of endogenous host cell

subunits and heterologous subunits, should, if possible, be inhibited to a significant extent by chemical, pharmacological and electrophysiological means.

The invention will now be described in greater detail with reference to the following non-limiting examples.

Example 1

Isolation of DNA Encoding Human nNACHR α_2 Subunits

RNA isolated from human thalamus tissue was used in synthesizing cDNA for λ gt11-based cDNA library. The library constructed from the cDNAs was screened for hybridization to a fragment of a rat nicotinic AChR α_2 subunit cDNA, using low stringency wash conditions.

Hybridizing clones were plaque-purified and characterized by restriction enzyme mapping and DNA sequence analysis. The insert DNA of one of the clones contained a translation initiation codon and nearly the complete coding sequence of an α_2 subunit of a human nicotinic AChR, except for ~77 bp at the 3' end. This insert was ligated with the insert of another clone containing the complete 3' end of the α_2 subunit coding sequence to generate a full-length α_2 subunit cDNA. The full-length cDNA was isolated and ligated into the polylinker of vector pIBI24 to generate h α_2 /pIBI24.

To verify the α_2 subunit coding sequence in h α_2 /pIBI24 near nucleotide 450, human thalamus cDNAs were subjected to nucleic acid amplification using oligonucleotides SE153 and SE154 as primers. These oligonucleotides correspond to human α_2 subunit-coding sequence located 5' and 3' of nucleotide 450. SE153, corresponding to the extreme 5' end of the α_2 subunit-coding sequence, also contained nucleotides corresponding

to a consensus ribosome binding site (RBS). Consequently, the product of the amplification contained an RBS (GCCACC) immediately 5' of the translation initiation codon.

- 5 The expected ~660-bp product was obtained from the amplification reaction. The product was digested with *EcoRI/SstI* and an ~560-bp fragment, comprising the 5' end of the $\alpha 2$ subunit coding sequence, was ligated with *EcoRI/SstI*-digested pIBI24 to create h $\alpha 2$ -5'/PIBI.
- 10 To generate full-length $\alpha 2$ subunit cDNA, a DNA fragment containing the 3' end of the $\alpha 2$ subunit coding sequence was ligated to the 5' fragment contained in h $\alpha 2$ -5'/PIBI as follows.

- Plasmid h $\alpha 2$ /PIBI24 was digested with *ClaI*,
15 followed by partial digestion with *SstI*. The 1.7-kb fragment containing the 3' portion of the $\alpha 2$ subunit coding sequence was isolated and ligated with *SstI*-digested h $\alpha 2$ -5'/PIBI to create PIBI-KE $\alpha 2$ RBS. This construct contains the correct full-length $\alpha 2$ subunit
20 coding sequence preceded immediately by an RBS.

Example 2

Preparation of Constructs for the Expression of Recombinant Human Neuronal Nicotinic AChR α_2 Subunits

- Isolated cDNAs encoding human neuronal
25 nicotinic AChR subunits were incorporated into vectors for use in expressing the subunits in mammalian host cells and for use in generating *in vitro* transcripts of the DNAs to be expressed in *Xenopus* oocytes. Several different vectors were utilized in preparing the
30 constructs as follows.

A. Construct for Expression of a Human nNACHR α_2 Subunit

DNA encoding a human neuronal nicotinic AChR α_2 subunit was subcloned into the pCMV-T7-3 general expression vector to create pCMV-KE α_2 RBSf. Plasmid pCMV-T7-3 (see Figure 1) is a pUC19-based vector that contains a CMV promoter/enhancer, SV40 splice donor/splice acceptor sites located immediately downstream of the promoter, a T7 bacteriophage RNA polymerase promoter positioned downstream of the SV40 splice sites, an SV40 polyadenylation signal downstream of the T7 promoter, and a polylinker between the T7 promoter and the polyadenylation signal. This vector thus contains all the regulatory elements required for expression of heterologous DNA in a mammalian host cell, wherein the heterologous DNA has been incorporated into the vector at the polylinker. In addition, because the T7 promoter is located just upstream of the polylinker, this plasmid can be used for synthesis of *in vitro* transcripts of heterologous DNA that has been subcloned into the vector at the polylinker. Figure 1 also shows a restriction map of pCMV-T7-2. This plasmid is identical to pCMV-T7-3 except that the restriction sites in the polylinker are in the opposite order as compared to the order in which they occur in pCMV-T7-3.

The insert in pIBI-KE α_2 RBS (see Example 1) was isolated as an *EcoRI* fragment and ligated with *EcoRI*-digested pCMV-T7-3 to generate pCMV-KE α_2 RBSf. Construct pCMV-KE α_2 RBSf contains the α_2 subunit coding sequence preceded immediately by an RBS and followed by 316 bp of 3' untranslated sequence. The coding sequence is operably positioned downstream of the T7 promoter thereby enabling the generation of *in vitro* transcripts of the cDNA.

B. Construct for Expression of a Human nNACHR β_2 Subunit

DNA encoding a human NACHR β_2 subunit (see U.S. Patent Application Serial Nos. 07/504,455 and 08/028,031 for such DNAs) was incorporated into expression vector pSP64T. Vector pSP64T [see Krieg and Melton (1984) *Nuc. Acids Res.* 12:7057-7070] is a modified form of vector pSP64 (Promega). The human NACHR β_2 subunit coding sequence (preceded by an RBS) was incorporated into pSP64T at a unique restriction enzyme cloning site that is flanked by 5' and 3' untranslated sequences from the *Xenopus* β -globin gene. These sequences are located downstream of the SP6 promoter contained in pSP64T. The resulting vector, pSP64T-KE β_2 RBS1, contains the human NACHR β_2 subunit coding sequence in operable association with SP6 transcription regulatory regions for the production of *in vitro* transcripts of the heterologous DNA.

Example 3

20 Expression of Recombinant Human Nicotinic AChR in Oocytes

Xenopus oocytes were injected with *in vitro* transcripts prepared from constructs containing DNA encoding α_2 and β_2 subunits. Electrophysiological measurements of the oocyte transmembrane currents were made using the two-electrode voltage clamp technique (see, e.g., Stuhmer (1992) *Meth. Enzymol.* 207:319-339).

1. Preparation of *in vitro* transcripts

Recombinant capped transcripts of pCMV-KE α_2 RBSf were synthesized from linearized plasmids using the mMessage mMachine T7 (Ambion Cat. #1334). Recombinant capped transcripts of pSP64T-KE β_2 RBS1 were synthesized from linearized plasmids using the MEGAscript SP6 in

vitro transcription kit according to the capped transcript protocol provided by the manufacturer (Catalog #1330 from AMBION, Inc., Austin, TX). The mass of each synthesized transcript was determined by UV absorbance and the integrity of each transcript was determined by electrophoresis through an agarose gel.

2. Electrophysiology

Xenopus oocytes were injected with 10 ng of each human nicotinic AChR subunit transcript per oocyte. The preparation and injection of oocytes were carried out as described by Dascal (1987) in *Crit. Rev. Biochem.* 22:317-387. Two-to-six days following mRNA injection, the oocytes were examined using the two-electrode voltage clamp technique. The cells were bathed in Ringer's solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl₂, 10 mM HEPES, pH 7.3) containing 1 μ M atropine. Cells were voltage-clamped at -80 mV. Data were acquired with Axotape software (AXON Instruments) at ~2 Hz. The agonists acetylcholine (ACh), nicotine, 1,1-dimethyl-4-phenylpiperazinium (DMPP) and cytisine were added at a concentration of about 1 μ M.

For the purpose of comparing the relative potencies of the four different agonists (i.e., nicotine, acetylcholine, cytisine and DMPP), oocytes were exposed to 1 μ M doses of each agonist, and the current responses recorded. The responses were normalized to the response of 1 μ M ACh (designated as 1.00 (see following table).

	<u>$\alpha_2\beta_2$ Normalized Response</u>
ACh	1.00
Nicotine	0.33 \pm 0.06
DMPP	0.40 \pm 0.15
5 Cytosine	0.09 \pm 0.04

n = 4

10 The recombinant oocytes exhibited detectable
current responses to all four agonists. The data in the
table presented above demonstrate that NACHRs expressed
in oocytes injected with transcripts of human α_2 and β_2
subunit cDNAs have the following relative sensitivities
15 to the agonists:

ACh > DMPP \approx nicotine > cytisine

Example 4

Recombinant Expression of Human nNACHR

α_2 Subunits in Mammalian Cells

20 Human embryonic kidney (HEK) 293 cells or other
suitable host cells can be transiently and stably
transfected with DNA encoding human neuronal nicotinic
AChR alpha and beta subunits. Transfectants are analyzed
for expression of nicotinic AChR using various assays,
25 e.g., electrophysiological methods, Ca^{2+} -sensitive
fluorescent indicator-based assays and nicotine-binding
assays.

A. Transient Transfection of Host Cells

In transient transfections, $\sim 2 \times 10^6$ host cells,
30 e.g., HEK293 cells, are transiently transfected with 18
 μg of plasmid(s) containing NACHR subunit DNAs according
to standard CaPO_4 transfection procedures [Wigler et al.

(1979) *Proc. Natl. Acad. Sci. USA* 76:1373-1376]. In addition, 2 μ g of plasmid pCMV β gal (Clontech Laboratories, Palo Alto, CA), which contains the *Escherichia coli* β -galactosidase gene fused to the CMV promoter, are co-transfected as a reporter gene for monitoring the efficiency of transfection. The transfectants are analyzed for β -galactosidase expression by measurement of β -galactosidase activity [Miller (1972) *Experiments in Molecular Genetics*, pp.352-355, Cold Spring Harbor Press]. Transfectants can also be analyzed for β -galactosidase expression by direct staining of the product of a reaction involving β -galactosidase and the X-gal substrate [Jones (1986) *EMBO* 5:3133-3142].

B. Stable Transfection of Host Cells

For stable transfection, host cells, such as HEK 293 cells, can be transfected using the calcium phosphate transfection procedure [*Current Protocols in Molecular Biology*, Vol. 1, Wiley Inter-Science, Supplement 14, Unit 9.1.1-9.1.9 (1990)]. Ten-cm plates, each containing one-to-two million host cells are transfected with 1 ml of DNA/calcium phosphate precipitate containing ~19 μ g total of NACHR α and β subunit construct DNA, and 1 μ g selectable marker DNA, e.g., pSV2neo. Typically, after 14 days of growth in selection media containing, for example, 1 μ g/ml G418, colonies form and are individually isolated by using cloning cylinders. The isolates are subjected to limiting dilution and screened to identify those that express the highest level of nicotinic AChR, as described below.

Example 5Characterization of Cell Lines Expressing nNACHRs

Recombinant cell lines generated by transfection with DNA encoding human neuronal nicotinic AChRs, such as those described in Example 3, can be further characterized using one or more of the following methods.

A. Fluorescent indicator-based assays

Activation of the ligand-gated nicotinic AChR by agonists leads to an influx of cations, including Ca^{++} , through the receptor channel. Ca^{++} entry into the cell through the channel can induce release of calcium contained in intracellular stores. Monovalent cation entry into the cell through the channel can also result in an increase in cytoplasmic Ca^{++} levels through depolarization of the membrane and subsequent activation of voltage-dependent calcium channels. Therefore, methods of detecting transient increases in intracellular calcium concentration can be applied to the analysis of functional nicotinic AChR expression. One method for measuring intracellular calcium levels relies on calcium-sensitive fluorescent indicators.

Calcium-sensitive indicators, such as fluo-3 (Catalog No. F-1241, Molecular Probes, Inc., Eugene, OR), are available as acetoxymethyl esters which are membrane permeable. When the acetoxymethyl ester form of the indicator enters a cell, the ester group is removed by cytosolic esterases, thereby trapping the free indicator in the cytosol. Interaction of the free indicator with calcium results in increased fluorescence of the indicator; therefore, an increase in the intracellular Ca^{2+} concentration of cells containing the indicator can be expressed directly as an increase in fluorescence. An

automated fluorescence detection system for assaying nicotinic AChR has been described in commonly assigned pending US Patent Application No. 07/812,254 and corresponding PCT Patent Application No. US92/11090.

5 Host cells that are transiently or stably co-transfected with DNA encoding alpha and beta subunits can be analyzed for expression of functional recombinant nicotinic AChR using the automated fluorescent indicator-based assay. The assay procedure is as follows.

10 Untransfected host cells and host cells that have been transfected with DNA encoding alpha and beta subunits are plated in the wells of a 96-well microtiter dish and loaded with fluo-3 by incubation for 2 hours at 20°C in a medium containing 20 μ M fluo-3, 0.2% Pluronic
15 F-127 in HBS (125 mM NaCl, 5 mM KCl, 1.8 mM CaCl₂, 0.62 mM MgSO₄, 6 mM glucose, 20 mM HEPES, pH 7.4). The cells are then washed with assay buffer (i.e., HBS). The antagonist d-tubocurarine can be added to some of the wells at a final concentration of 10 μ M. The microtiter
20 dish is then placed into a fluorescence plate reader and the basal fluorescence of each well is measured and recorded before addition of 200 μ M nicotine to the wells. The fluorescence of the wells is monitored repeatedly during a period of approximately 60 seconds following
25 addition of nicotine.

B. Northern or slot blot analysis for expression of α - and/or β -subunit encoding messages

 Total RNA is isolated from $\sim 1 \times 10^7$ cells and 10-15 μ g of RNA from each cell type is used for northern
30 or slot blot hybridization analysis. The inserts from human neuronal NAChR-encoding plasmids can be nick-translated and used as probe. In addition, the β -actin gene sequence (Cleveland et al. (1980) Cell 20:95-105) can be nick-translated and used as a control probe on

duplicate filters to confirm the presence or absence of RNA on each blot and to provide a rough standard for use in quantitating differences in α - or β -specific mRNA levels between cell lines. Typical northern and slot
5 blot hybridization and wash conditions are as follows:

hybridization in 5x SSPE, 5X Denhardt's solution, 50% formamide, at 42°C followed by washing in 0.2x SSPE, 0.1% SDS, at 65°C.

C. Nicotine-binding assay

10 Cell lines generated by transfection with human neuronal nicotinic AChR α - or α - and β -subunit-encoding DNA can be analyzed for their ability to bind nicotine, for example, as compared to control cell lines: neuronally-derived cell lines PC12 (Boulter et al.,
15 (1986), supra; ATCC #CRL1721) and IMR32 (Clementi, et al. (1986); Int. J. Neurochem. 47:291-297; ATCC #CCL127), and muscle-derived cell line BC3H1 (Patrick, et al., (1977); J. Biol. Chem. 252:2143-2153). Negative control cells (i.e., host cells from which the transfectants were
20 prepared) are also included in the assay. The assay is conducted as follows:

Just prior to being assayed, transfected cells are removed from plates by scraping. Positive control cells used are PC12, BC3H1, and IMR32 (which had been
25 starved for fresh media for seven days). Control cell lines are removed by rinsing in 37°C assay buffer (50mM Tris/HCl, 1 mM MgCl₂, 2 mM CaCl₂, 120 mM NaCl, 3 mM EDTA, 2 mg/ml BSA and 0.1 % aprotinin at pH7.4). The cells are washed and resuspended to a concentration of $1 \times 10^6/250$
30 μ l. To each plastic assay tube is added 250 μ l of the cell solution, 15 nM ³H-nicotine, with or without 1 mM unlabeled nicotine, and assay buffer to make a final volume of 500 μ l. The assays for the transfected cell

lines are incubated for 30 min at room temperature; the assays of the positive control cells are incubated for 2 min at 1°C. After the appropriate incubation time, 450 µl aliquots of assay volume are filtered through Whatman GF/C glass fiber filters which has been pretreated by incubation in 0.05% polyethyleneimine for 24 hours at 4°C. The filters are then washed twice, with 4 ml each wash, with ice cold assay buffer. After washing, the filters are dried, added to vials containing 5 ml scintillation fluid and radioactivity is measured.

D. ⁸⁶Rb ion-flux assay

The ability of nicotine or nicotine agonists and antagonists to mediate the influx of ⁸⁶Rb into transfected and control cells has been found to provide an indication of the presence of functional AChRs on the cell surface. The ⁸⁶Rb ion-flux assay is conducted as follows:

1. The night before the experiment, cells are plated at 2×10^6 per well (i.e., 2 ml per well) in a 6-well polylysine-coated plate.

2. The culture medium is decanted and the plate washed with 2 ml of assay buffer (50 mM HEPES, 260 mM sucrose, 5.4 mM KCl, 1.8 mM CaCl₂, 0.8 mM MgSO₄, 5.5 mM glucose) at room temperature.

3. The assay buffer is decanted and 1 ml of assay buffer, containing 3 µCi/ml ⁸⁶Rb, with 5 mM ouabain and agonist or antagonist in a concentration to effect a maximum response, is added.

4. The plate is incubated on ice at 1°C for 4 min.

5. The buffer is decanted into a waste container and each well was washed with 3 ml of assay buffer, followed by two washes of 2 ml each.

6. The cells are lysed with 2 x 0.5 ml of 0.2% SDS per well and transferred to a scintillation vial containing 5 ml of scintillation fluid.

7. The radioactivity contained in each vial is measured and the data calculated.

Positive control cells provided the following data in this assay:

	PC12		IMR32	
	EC ₅₀	Maximum response	EC ₅₀	Maximum response
<u>Agonist</u>				
nicotine	52 μ M	2.1X ^a	18 μ M	7.7X ^a
CCh [*]	35 μ M	3.3X ^b	230 μ M	7.6X ^c
cytisine	57 μ M	3.6X ^d	14 μ M	10X ^e
<u>Antagonist</u>				
d-tubocurarine	0.81 μ M		2.5 μ M	
mecamylamine	0.42 μ M		0.11 μ M	
hexamethonium	nd ^f		22 μ M	
atropine	12.5 μ M		43 μ M	

* CCh = carbamylcholine

^a 200 μ M nicotine

^b 300 μ M CCh

^c 3mM CCh

^d 1mM cytisine

^e 100 μ M cytisine

^f nd = not determined

E. Electrophysiological Analysis of Mammalian Cells Transfected with Human Neuronal Nicotinic AChR Subunit-encoding DNA

Electrophysiological measurements may be used to assess the activity of recombinant receptors or to assess the ability of a test compound to potentiate, antagonize or otherwise modulate the magnitude and duration of the flow of cations through the ligand-gated recombinant AChR. The function of the expressed neuronal AChR can be assessed by a variety of electrophysiological techniques, including two-electrode voltage clamp and patch clamp methods. The cation-conducting channel intrinsic to the AChR opens in response to acetylcholine (ACh) or other nicotinic cholinergic agonists, permitting

the flow of transmembrane current carried predominantly by sodium and potassium ions under physiological conditions. This current can be monitored directly by voltage clamp techniques. In preferred embodiments, 5 transfected mammalian cells or injected oocytes are analyzed electrophysiologically for the presence of AChR agonist-dependent currents.

While the invention has been described in detail with reference to certain preferred embodiments 10 thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Elliot, Kathryn J.
Ellis, Steven B.
Harpold, Michael M.
- (ii) TITLE OF INVENTION: HUMAN NEURONAL NICOTINIC ACETYLCHOLINE
RECEPTOR COMPOSITIONS AND METHODS EMPLOYING SAME
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
 - (B) STREET: 444 South Flower Street, Suite 2000
 - (C) CITY: Los Angeles
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 90071
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE: 08-NOV-1993
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/028,031
 - (B) FILING DATE: 08-MAR-1993
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Reiter, Stephen E.
 - (B) REGISTRATION NUMBER: 31,192
 - (C) REFERENCE/DOCKET NUMBER: P41 9499
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 619-546-4737
 - (B) TELEFAX: 619-546-9392

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2277 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: both
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 166..1755

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAATGACCTG TTTTCTTCTG TAACCACAGG TTCGGTGGTG AGAGGAACCT TCGCAGAATC

CAGCAGAATC CTCACAGAAT CCAGCAGCAG CTCTGCTGGG GACATGGTCC ATGGTGCAAC	120
CCACAGCAAA GCCCTGACCT GACCTCCTGA TGCTCAGGAG AAGCC ATG GGC CCC Met Gly Pro 1	174
TCC TGT CCT GTG TTC CTG TCC TTC ACA AAG CTC AGC CTG TGG TGG CTC Ser Cys Pro Val Phe Leu Ser Phe Thr Lys Leu Ser Leu Trp Trp Leu 5 10 15	222
CTT CTG ACC CCA GCA GGT GGA GAG GAA GCT AAG CGC CCA CCT CCC AGG Leu Leu Thr Pro Ala Gly Gly Glu Glu Ala Lys Arg Pro Pro Pro Arg 20 25 30 35	270
GCT CCT GGA GAC CCA CTC TCC TCT CCC AGT CCC ACG GCA TTG CCG CAG Ala Pro Gly Asp Pro Leu Ser Ser Pro Ser Pro Thr Ala Leu Pro Gln 40 45 50	318
GGA GGC TCG CAT ACC GAG ACT GAG GAC CGG CTC TTC AAA CAC CTC TTC Gly Gly Ser His Thr Glu Thr Glu Asp Arg Leu Phe Lys His Leu Phe 55 60 65	366
CGG GGC TAC AAC CGC TGG GCG CGC CCG GTG CCC AAC ACT TCA GAC GTG Arg Gly Tyr Asn Arg Trp Ala Arg Pro Val Pro Asn Thr Ser Asp Val 70 75 80	414
GTG ATT GTG CGC TTT GGA CTG TCC ATC GCT CAG CTC ATC GAT GTG GAT Val Ile Val Arg Phe Gly Leu Ser Ile Ala Gln Leu Ile Asp Val Asp 85 90 95	462
GAG AAG AAC CAA ATG ATG ACC ACC AAC GTC TGG CTA AAA CAG GAG TGG Glu Lys Asn Gln Met Met Thr Thr Asn Val Trp Leu Lys Gln Glu Trp 100 105 110 115	510
AGC GAC TAC AAA CTG CGC TGG AAC CCC GCT GAT TTT GGC AAC ATC ACA Ser Asp Tyr Lys Leu Arg Trp Asn Pro Ala Asp Phe Gly Asn Ile Thr 120 125 130	558
TCT CTC AGG GTC CCT TCT GAG ATG ATC TGG ATC CCC GAC ATT GTT CTC Ser Leu Arg Val Pro Ser Glu Met Ile Trp Ile Pro Asp Ile Val Leu 135 140 145	606
TAC AAC AAT GCA GAT GGG GAG TTT GCA GTG ACC CAC ATG ACC AAG GCC Tyr Asn Asn Ala Asp Gly Glu Phe Ala Val Thr His Met Thr Lys Ala 150 155 160	654
CAC CTC TTC TCC ACG GGC ACT GTG CAC TGG GTG CCC CCG GCC ATC TAC His Leu Phe Ser Thr Gly Thr Val His Trp Val Pro Pro Ala Ile Tyr 165 170 175	702
AAG AGC TCC TGC AGC ATC GAC GTC ACC TTC TTC CCC TTC GAC CAG CAG Lys Ser Ser Cys Ser Ile Asp Val Thr Phe Phe Pro Phe Asp Gln Gln 180 185 190 195	750
AAC TGC AAG ATG AAG TTT GGC TCC TGG ACT TAT GAC AAG GCC AAG ATC Asn Cys Lys Met Lys Phe Gly Ser Trp Thr Tyr Asp Lys Ala Lys Ile 200 205 210	798
GAC CTG GAG CAG ATG GAG CAG ACT GTG GAC CTG AAG GAC TAC TGG GAG Asp Leu Glu Gln Met Glu Gln Thr Val Asp Leu Lys Asp Tyr Trp Glu 215 220 225	846
AGC GGC GAG TGG GCC ATC GTC AAT GCC ACG GGC ACC TAC AAC AGC AAG Ser Gly Glu Trp Ala Ile Val Asn Ala Thr Gly Thr Tyr Asn Ser Lys 230 235 240	894

AAG TAC GAC TGC TGC GCC GAG ATC TAC CCC GAC GTC ACC TAC GCC TTC Lys Tyr Asp Cys Cys Ala Glu Ile Tyr Pro Asp Val Thr Tyr Ala Phe 245 250 255	942
GTC ATC CGG CGG CTG CCG CTC TTC TAC ACC ATC AAC CTC ATC ATC CCC Val Ile Arg Arg Leu Pro Leu Phe Tyr Thr Ile Asn Leu Ile Ile Pro 260 265 270 275	990
TGC CTG CTC ATC TCC TGC CTC ACT GTG CTG GTC TTC TAC CTG CCC TCC Cys Leu Leu Ile Ser Cys Leu Thr Val Leu Val Phe Tyr Leu Pro Ser 280 285 290	1038
GAC TGC GGC GAG AAG ATC ACG CTG TGC ATT TCG GTG CTG CTG TCA CTC Asp Cys Gly Glu Lys Ile Thr Leu Cys Ile Ser Val Leu Leu Ser Leu 295 300 305	1086
ACC GTC TTC CTG CTG CTC ATC ACT GAG ATC ATC CCG TCC ACC TCG CTG Thr Val Phe Leu Leu Leu Ile Thr Glu Ile Ile Pro Ser Thr Ser Leu 310 315 320	1134
GTC ATC CCG CTC ATC GGC GAG TAC CTG CTG TTC ACC ATG ATC TTC GTC Val Ile Pro Leu Ile Gly Glu Tyr Leu Leu Phe Thr Met Ile Phe Val 325 330 335	1182
ACC CTG TCC ATC GTC ATC ACC GTC TTC GTG CTC AAT GTG CAC CAC CGC Thr Leu Ser Ile Val Ile Thr Val Phe Val Leu Asn Val His His Arg 340 345 350 355	1230
TCC CCC AGC ACC CAC ACC ATG CCC CAC TGG GTG CGG GGG GCC CTT CTG Ser Pro Ser Thr His Thr Met Pro His Trp Val Arg Gly Ala Leu Leu 360 365 370	1278
GGC TGT GTG CCC CGG TGG CTT CTG ATG AAC CGG CCC CCA CCA CCC GTG Gly Cys Val Pro Arg Trp Leu Leu Met Asn Arg Pro Pro Pro Pro Val 375 380 385	1326
GAG CTC TGC CAC CCC CTA CGC CTG AAG CTC AGC CCC TCT TAT CAC TGG Glu Leu Cys His Pro Leu Arg Leu Lys Leu Ser Pro Ser Tyr His Trp 390 395 400	1374
CTG GAG AGC AAC GTG GAT GCC GAG GAG AGG GAG GTG GTG GTG GAG GAG Leu Glu Ser Asn Val Asp Ala Glu Glu Arg Glu Val Val Val Glu Glu 405 410 415	1422
GAG GAC AGA TGG GCA TGT GCA GGT CAT GTG GCC CCC TCT GTG GGC ACC Glu Asp Arg Trp Ala Cys Ala Gly His Val Ala Pro Ser Val Gly Thr 420 425 430 435	1470
CTC TGC AGC CAC GGC CAC CTG CAC TCT GGG GCC TCA GGT CCC AAG GCT Leu Cys Ser His Gly His Leu His Ser Gly Ala Ser Gly Pro Lys Ala 440 445 450	1518
GAG GCT CTG CTG CAG GAG GGT GAG CTG CTG CTA TCA CCC CAC ATG CAG Glu Ala Leu Leu Gln Glu Gly Glu Leu Leu Leu Ser Pro His Met Gln 455 460 465	1566
AAG GCA CTG GAA GGT GTG CAC TAC ATT GCC GAC CAC CTG CGG TCT GAG Lys Ala Leu Glu Gly Val His Tyr Ile Ala Asp His Leu Arg Ser Glu 470 475 480	1614
GAT GCT GAC TCT TCG GTG AAG GAG GAC TGG AAG TAT GTT GCC ATG GTC Asp Ala Asp Ser Ser Val Lys Glu Asp Trp Lys Tyr Val Ala Met Val 485 490 495	1662
ATC GAC AGG ATC TTC CTC TGG CTG TTT ATC ATC GTC TGC TTC CTG GGG Ile Asp Arg Ile Phe Leu Trp Leu Phe Ile Ile Val Cys Phe Leu Gly 500 505 510 515	1710

46

ACC ATC GGC CTC TTT CTG CCT CCG TTC CTA GCT GGA ATG ATC TGACTGCACC	1762
Thr Ile Gly Leu Phe Leu Pro Pro Phe Leu Ala Gly Met Ile	
520 525 530	
TCCCTCGAGC TGGCTCCCAG GGCAAAGGGG AGGGTTCTTG GATGTGGAAG GGCTTTGAAC	1822
AATGTTTAGA TTTGGAGATG AGCCCAAAGT GCCAGGGAGA ACAGCCAGGT GAGGTGGGAG	1882
GTTGGAGAGC CAGGTGAGGT CTCTCTAAGT CAGGCTGGGG TTGAAGTTTG GAGTCTGTCC	1942
GAGTTTGCAG GGTGCTGAGC TGTATGGTCC AGCAGGGGAG TAATAAGGGC TCTTCCGGAA	2002
GGGGAGGAAG CGGGAGGCAG GGCCTGCACC TGATGTGGAG GTACAGGGCA GATCTTCCCT	2062
ACCGGGGAGG GATGGATGGT TGGATACAGG TGGCTGGGCT ATTCCATCCA TCTGGAAGCA	2122
CATTGAGCC TCCAGGCTTC TCCTTGACGT CATTCCTCTC CTCCTTGCT CCAAAATGGC	2182
TCTGCACCAG CCGGCCCCCA GGAGGTCTGG CAGAGCTGAG AGCCATGGCC TGCAGGGGCT	2242
CCATATGTCC CTACGCGTGC AGCAGGCAAA CAAGA	2277

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 529 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Gly Pro Ser Cys Pro Val Phe Leu Ser Phe Thr Lys Leu Ser Leu	
1 5 10 15	
Trp Trp Leu Leu Leu Thr Pro Ala Gly Gly Glu Glu Ala Lys Arg Pro	
20 25 30	
Pro Pro Arg Ala Pro Gly Asp Pro Leu Ser Ser Pro Ser Pro Thr Ala	
35 40 45	
Leu Pro Gln Gly Gly Ser His Thr Glu Thr Glu Asp Arg Leu Phe Lys	
50 55 60	
His Leu Phe Arg Gly Tyr Asn Arg Trp Ala Arg Pro Val Pro Asn Thr	
65 70 75 80	
Ser Asp Val Val Ile Val Arg Phe Gly Leu Ser Ile Ala Gln Leu Ile	
85 90 95	
Asp Val Asp Glu Lys Asn Gln Met Met Thr Thr Asn Val Trp Leu Lys	
100 105 110	
Gln Glu Trp Ser Asp Tyr Lys Leu Arg Trp Asn Pro Ala Asp Phe Gly	
115 120 125	
Asn Ile Thr Ser Leu Arg Val Pro Ser Glu Met Ile Trp Ile Pro Asp	
130 135 140	
Ile Val Leu Tyr Asn Asn Ala Asp Gly Glu Phe Ala Val Thr His Met	
145 150 155 160	
Thr Lys Ala His Leu Phe Ser Thr Gly Thr Val His Trp Val Pro Pro	
165 170 175	

47

Ala Ile Tyr Lys Ser Ser Cys Ser Ile Asp Val Thr Phe Phe Pro Phe
 180 185 190
 Asp Gln Gln Asn Cys Lys Met Lys Phe Gly Ser Trp Thr Tyr Asp Lys
 195 200 205
 Ala Lys Ile Asp Leu Glu Gln Met Glu Gln Thr Val Asp Leu Lys Asp
 210 215 220
 Tyr Trp Glu Ser Gly Glu Trp Ala Ile Val Asn Ala Thr Gly Thr Tyr
 225 230 235 240
 Asn Ser Lys Lys Tyr Asp Cys Cys Ala Glu Ile Tyr Pro Asp Val Thr
 245 250 255
 Tyr Ala Phe Val Ile Arg Arg Leu Pro Leu Phe Tyr Thr Ile Asn Leu
 260 265 270
 Ile Ile Pro Cys Leu Leu Ile Ser Cys Leu Thr Val Leu Val Phe Tyr
 275 280 285
 Leu Pro Ser Asp Cys Gly Glu Lys Ile Thr Leu Cys Ile Ser Val Leu
 290 295 300
 Leu Ser Leu Thr Val Phe Leu Leu Leu Ile Thr Glu Ile Ile Pro Ser
 305 310 315 320
 Thr Ser Leu Val Ile Pro Leu Ile Gly Glu Tyr Leu Leu Phe Thr Met
 325 330 335
 Ile Phe Val Thr Leu Ser Ile Val Ile Thr Val Phe Val Leu Asn Val
 340 345 350
 His His Arg Ser Pro Ser Thr His Thr Met Pro His Trp Val Arg Gly
 355 360 365
 Ala Leu Leu Gly Cys Val Pro Arg Trp Leu Leu Met Asn Arg Pro Pro
 370 375 380
 Pro Pro Val Glu Leu Cys His Pro Leu Arg Leu Lys Leu Ser Pro Ser
 385 390 395 400
 Tyr His Trp Leu Glu Ser Asn Val Asp Ala Glu Glu Arg Glu Val Val
 405 410 415
 Val Glu Glu Glu Asp Arg Trp Ala Cys Ala Gly His Val Ala Pro Ser
 420 425 430
 Val Gly Thr Leu Cys Ser His Gly His Leu His Ser Gly Ala Ser Gly
 435 440 445
 Pro Lys Ala Glu Ala Leu Leu Gln Glu Gly Glu Leu Leu Ser Pro
 450 455 460
 His Met Gln Lys Ala Leu Glu Gly Val His Tyr Ile Ala Asp His Leu
 465 470 475 480
 Arg Ser Glu Asp Ala Asp Ser Ser Val Lys Glu Asp Trp Lys Tyr Val
 485 490 495
 Ala Met Val Ile Asp Arg Ile Phe Leu Trp Leu Phe Ile Ile Val Cys
 500 505 510
 Phe Leu Gly Thr Ile Gly Leu Phe Leu Pro Pro Phe Leu Ala Gly Met
 515 520 525
 Ile

THAT WHICH IS CLAIMED:

1. Isolated DNA comprising a sequence of nucleotides encoding an α_2 subunit of a human neuronal nicotinic acetylcholine receptor.
2. DNA according to claim 1 wherein the nucleotides of said DNA encode the amino acid sequence set forth in SEQ. ID No. 2.
3. DNA according to claim 1 wherein the nucleotides of said DNA hybridize to substantially the entire coding sequence (nucleotides 166-1755) set forth in SEQ. ID No. 1 under high stringency conditions.
4. DNA according to claim 1 wherein said DNA has substantially the same nucleotide sequence as nucleotides 166-1755 set forth in SEQ. ID No. 1.
5. Cells containing at least one DNA according to claim 1.
6. Cells according to claim 5, wherein said cells are selected from bacterial cells, eukaryotic cells and amphibian oöcytes.
- ~~7. Cells according to claim 5, further~~
containing DNA encoding a β subunit of human neuronal nicotinic acetylcholine receptor.
8. Cells according to claim 7 wherein said β subunit is selected from β_2 or β_4 .

9. Cells according to claim 5 wherein said cells express functional neuronal nicotinic acetylcholine receptors that contain one or more subunits encoded by said DNA.

10. A method of screening compounds to identify compounds which modulate the activity of human neuronal nicotinic acetylcholine receptors, said method comprising determining the effect of a compound on the neuronal nicotinic acetylcholine receptor activity in test cells according to claim 7, compared to the effect on control cells or to the neuronal nicotinic acetylcholine receptor activity of the cells in the absence of the compound,

wherein control cells are substantially identical to the test cells, but control cells do not express nicotinic acetylcholine receptors.

11. Recombinant human neuronal nicotinic acetylcholine receptor α_2 subunit.

12. A recombinant human neuronal nicotinic acetylcholine receptor comprising the subunit of claim 11.

13. Human neuronal nicotinic acetylcholine receptor according to claim 12, further comprising a human neuronal nicotinic acetylcholine receptor beta subunit.

14. A method for identifying functional neuronal nicotinic acetylcholine receptor subunits and combinations thereof, said method comprising:

(a) introducing at least one DNA according to
5 claim 1, or RNA complementary thereto, and optionally DNA encoding at least one beta subunit of a human neuronal

nicotinic acetylcholine receptor, or RNA complementary thereto, into eukaryotic cells; and

- (b) assaying for neuronal nicotinic
- 10 acetylcholine receptor activity in cells of step (a), wherein the activity is mediated by a receptor containing one or more of the subunits encoded by said introduced DNA.


15. Isolated mRNA encoded by the DNA of Claim 1.

16. Cells containing mRNA according to claim 15.

- 5 17. Cells according to claim 16 wherein said cells further contain mRNA encoding a beta subunit of a human neuronal nicotinic acetylcholine receptor.
-

1 / 1

FIGURE 1



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/12859

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 14/705; C12N 15/00; C12Q 1/00

US CL :435/4, 69.1, 240.1; 530/350; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/4, 69.1, 240.1; 530/350; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Medline, Dialog, WPI

search terms: nicotinic acetylcholine receptor, human, neuronal, subunits, cloning

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Genomics, Volume 13, issued 1992, Anand et al, "Chromosomal Localization of Seven Neuronal Nicotinic Acetylcholine Receptor Subunit Genes in Humans", pages 962-967, see pages 963 and 964.	1-17
Y	Neuron, Volume 1, issued March 1988, Deneris et al, "Primary Structure and Expression of $\beta 2$: A Novel Subunit of Neuronal Nicotinic Acetylcholine Receptors", pages 45-54, see pages 46 and 47.	7-10, 14, 17
X	Society for Neuroscience, Abstracts, Volume 16, Part 1, issued 1990, Nash et al, "Molecular Cloning and Expression of Human Neuronal Nicotinic Acetylcholine Receptor Subunits", page 10, Abstract 9.10, see entire abstract.	1-6, 11-13, 15, 16
Y		7-10, 14, 17

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	A	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

24 JANUARY 1995

Date of mailing of the international search report

08 FEB 1995

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Sally P. Teng

Telephone No. (703) 308-0196

International application No.
PCT/US94/12859

International application No.
PCT/US94/12859

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>Science, Volume 240, issued 15 April 1988, Wada et al, "Functional Expression of a New Pharmacological Subtype of Brain Nicotinic Acetylcholine Receptor", pages 330-334, see entire document.</p>	1-17